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The effect of HIV infection on overdose mortality
Cunlin Wanga, David Vlahova,b, Noya Galaia, Stephen R. Colea,
Joseph Baretaa, Robin Pollinia, Shruti H. Mehtaa, Kenrad E. Nelsona
and Sandro Galeab
Objectives: To quantify the association of HIV infection with overdose mortality and
explore the potential mechanisms.
Design: A prospective cohort study.
Methods: A total of 1927 actively injecting drug users who were HIV seronegative at
baseline, of whom 308 later HIV seroconverted, were followed semi-annually for death
from 1988 to 2001. Survival analyses using marginal structural and standard Cox
models were used to evaluate the effect of HIV infection on the risk of overdose
mortality.
Results: Overdose death rates were higher in HIV-seropositive than HIV-seronegative
drug users: 13.9 and 5.6 per 1000 person-years, respectively (P < 0.01). The hazard
ratio (HR) was 2.54 [95% confidence interval (CI) 1.47, 4.38] for the marginal structural
model and 2.06 (95% CI 1.25, 3.38) for the standard Cox model, both adjusted for
demographics, drug injection characteristics, alcohol abuse, substance abuse treat-
ment, and sexual orientation. Adjusting for possible time-varying mediators (i.e. drug
use, medical conditions and healthcare access) in extended marginal structural models
reduced the effect of HIV on overdose mortality by 30% (HR 1.82, 95% CI 1.01, 3.30).
Abnormal liver function was associated with a higher risk of overdose mortality (HR
2.00, 95% CI 1.05, 3.84); adjustment for this further reduced the effect of HIV on
overdose mortality.
Conclusion: HIV infection was associated with a higher risk of overdose mortality.
Drug use behavior, systematic disease and liver damage associated with HIV infection
appeared to account for a substantial portion of this association. The data suggest a
group to target with interventions to reduce overdose mortality rates.
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Introduction
Among injection drug users (IDU), two commonly
reported causes of death include drug overdose, and in
HIV epidemic areas, AIDS. Whereas the HIV epidemic
among this group has attracted substantial attention over
the past two decades, in the United States, Europe and
Australia, drug overdose and related deaths have also been
consistently increasing in recent years [1–4]. Meanwhile,
data from most western European countries and north
America have shown that the number of individuals using
opiates and cocaine has either been stable or declined in
the 1990s [5]. Moreover, this trend of increase in overdose
deaths was also observed within drug user cohorts [6–9].
Interestingly, cohort studies have also shown that the
increase in overdose deaths paralleled the increase in
AIDS mortality [6,8–10]. So far, only a few studies have
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addressed this association of HIV and overdose mortality
[6,7,9,11–14]. These studies have been limited by:
(i) including mostly HIV-prevalent drug users at baseline
whose date of HIV seroconversion was unknown;
(ii) failing to adjust for important confounders that can
be associated with both HIV infection and drug overdose;
or (iii) having either a small sample or a short follow-up
period, therefore reporting only a few events.
Meanwhile, the mechanism of fatal overdose remains
unclear [2,15–17]. Progress from recent research has
provided more explanations on the possible mechanism of
drug overdose, which included loss of tolerance,
metabolic variation, interaction of poly-drug use, and
systematic disease [2,4,18]. These data have revealed
characteristics that can serve as the basis for hypothesizing
pathways to explore the association of HIV infection and
overdose death.
The first hypothesis for an HIVand overdose association is
a reduction in drug tolerance as a result of the effects of
HIV infection. Overdose deaths occur at greater
frequency when drug users are discharged from drug
treatment or released from prison, presumably because of
relapse using similar doses but with less tolerance. For
HIV, as infection progresses, symptoms can interfere with
drug use patterns, resulting in reduced, or intermittent
use, during which tolerance subsides. A resumption of
use, especially with doses used when more tolerant, could
be a possible consideration in overdose mortality. Second,
for opiate users, drug-induced respiratory depression is
probably a primary reason for overdose death. In
combination with current or previous pulmonary disease,
which is more common in HIV-seropositive drug users
than seronegative drug users, overdose may reflect an
underlying susceptibility to respiratory depression
among HIV-infected drug users, especially in those with
advanced immunosuppression [19]. Third, hepatic dis-
eases may also be associated with a higher risk of overdose
mortality by affecting opiate metabolism. The prevalence
of hepatitis C virus (HCV) infection among IDU is high,
varying from 60 to 90% [20–22]. Studies have shown that
the progression of HCV can be accelerated in those with
HIV infection [23–25], which may, in turn, impair the
liver’s capability to metabolize morphine. Fourth, damage
of the central nervous system, which can be caused by
drugs, HIV infection and head trauma associated with
violence among drug users [26,27], may increase the
vulnerability of the inhibitory effects of opiates on the
respiratory system [6], or impair their cognitive function,
which can affect the ability to judge risky drug use
behavior. Fifth, damage of immune system can under-
mine the immune response of chronic drug users to
produce moderate affinity antibodies and reduce the
circulating free fraction of active heroin metabolites [28].
In this study we explored the effect of HIV infection on
the risk of overdose mortality and the potential
mechanisms for this association among 1927 active
IDU, and compared HIV seroconverters with HIV-




Participants were enrolled in the AIDS Linked to the
Intravenous Experience (ALIVE) study in Baltimore,
MD, USA [29]. IDU were recruited through community
outreach from 1988 to 1989, with additional recruitment
in 1994 and 1998. All participants were followed with
semi-annual visits that included a questionnaire interview
that obtained information for the preceding 6 months on
sexual behavior, drug use, medical history, and anti-
retroviral treatment if HIV seropositive, a clinical
examination, and venipuncture for laboratory tests
including CD4 cell count and liver function.
Ascertainment of overdose death
Death was ascertained through the National Death Index
(NDI), with confirmation through death certificates and
chief medical examiner reports. This study was truncated
at December 2001 because of the approximate 2 year lag
period from the NDI. Overdose mortality was deter-
mined in two ways. Approximately 60% of overdose
deaths in the ALIVE study were confirmed by autopsy
reports. For deaths for which autopsy reports were
unavailable, overdose death was determined when it was
the only cause of death from NDI-Plus, and the death
certificate as well as supplemental medical records were
reviewed by a clinical endpoints committee. In the study,
after excluding overdose deaths that occurred 2 years after
the last follow-up visit, there was a total of 92 overdose
deaths, of whom 67 were HIV seropositive.
Laboratory assays
HIV antibodies were assayed using commercial tests and
were interpreted using standard criteria. T-cell subsets
were determined by flow cytometry. Abnormal liver
function was determined by commercial assay, and
defined as being out of the normal range for both total
serum bilirubin (0.1–1.0 mg/dl) and serum albumin
(3.5–5.0 g/dl) [30,31].
Statistical analysis
Mortality rates were calculated as the number of deaths
divided by the number of person-years. Person-years was
determined from the date of staggered entry [32] to the
date of death, dropout, or the date of administrative
censoring. The censoring can be the end of the study, 31
December 2001, the date of the initiation of highly active
antiretroviral therapy defined by the International AIDS
Society guidelines [33], the date of the last follow-up visit
if the visit was more than one year before 31 December
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2001, or if the date of death was more than 2 years after
the last follow-up. The complement of the extended
Kaplan–Meier and log-rank test were used to compare
the time to overdose death between HIV seroconverted
and seronegative groups. The extended Kaplan–Meier
allows HIV seroconverters to contribute person-time to
the HIV-1-seronegative group before seroconversion via
late entries into the HIV seroconverters group [32,34].
The marginal structural Cox regression models [35,36]
were used to estimate the total effect of HIV infection on
overdose mortality, accounting for factors potentially
associated with both HIV seroconversion and overdose
mortality, but could also be affected by HIV infection. In
our analysis, at the univariate model, we considered all
collected variables including demographics, social eco-
nomics status, drug abuse behavior (including both
inhaled or ingested use: crack, heroin, cocaine, mar-
ijuana, street methadone; injection drug use: type of drug
injected, injection frequency, needle sharing, use of
shooting gallery; and drug abuse treatment: detoxification
or methadone programme enrollment), alcohol abuse and
sexual behavior. Factors identified as potentially signi-
ficant (P < 0.1) were included into the multivariate
model. As described elsewhere [35–37], marginal
structural models weight person-time proportionally to
the conditional probability of exposure given time-
dependent confounders. The weights are a generalization
of Horwitz–Thompson weights, and are generated using
the same method used to create the propensity score. The
weighted data reflect a pseudo-population in which the
time-varying covariates do not predict HIV seroconver-
sion, but the impact of HIV infection on the hazard of
overdose death is still the same as in the original
population. Therefore, the weighted data remove the
association of confounders with HIV seroconversion, but
preserve the association of HIV and overdose deaths. We
also stabilized the weights by baseline characteristics, and
subsequently included these baseline characteristics in the
marginal structural model. In addition, we also fit
standard time-dependent Cox regression models for
comparisons with marginal structural models. Robust
variances were estimated to account for the correlation
between observations from the same participants.
Although not a perfect method [38], previous studies have
suggested that to explore the mechanism of exposure
effect on outcome, time-dependent covariates that may
serve as ‘intermediates’ can be added into the model to see
the corresponding change on the association between
exposure and outcome [39]. This type of analysis has been
applied in studies to identify mediators [40] and surrogate
endpoints [41]. In the present analysis, to explore
potential time-varying mediators that lie on a pathway
between HIV infection and overdose mortality, we
compared the total effect of HIV on overdose mortality
from the standard marginal structural model to an
approximated direct effect of HIV on overdose mortality
that was not through the time-varying mediator, and was
estimated from a marginal structural model with that
time-varying mediator included as a covariate. The direct
effect was approximated by assuming that there were no
confounders of the mediators and overdose mortality.
The mediators we explored included drug and alcohol
abuse characteristics, substance abuse treatment, medical
conditions, healthcare access and abnormal liver function.
Results
Baseline characteristics
The study consisted of 1927 participants who were
actively using drugs during the 6 months before the
baseline. Among them, 1619 were persistently HIV
seronegative and 308 HIV seroconverted during the
follow-up. At baseline, participants who later HIV
seroconverted were more likely than persistently ser-
onegative drug users to be younger (median age 31.0
versus 35.1 years, P < 0.01), to be black; and were less
likely to be educated, or to be ever married (Table 1). In
addition, HIV seroconverters were more likely than
uninfected drug users to have initiated drug use at an
earlier age, to have used heroin, and to have a homosexual
orientation, but were less likely to report previous
methadone treatment. There were no significant differ-
ences between the two groups with respect to the other
factors.
Predictors of HIV seroconversion
As shown in Table 2, HIV seroconversion was positively
associated (P < 0.05) with younger age at baseline,
younger age of drug initiation, injecting drugs, and male
homosexuality, and to a lesser degree with shooting
gallery use (P < 0.07); but was inversely associated
(P < 0.05) with marijuana use, methadone treatment,
and detoxification; and marginally associated with
employment (P ¼ 0.06). Gender, race, education, marital
status, or needle sharing did not discriminate HIV
seroconversion.
Overall effect of HIV infection on overdose
mortality
As shown in Table 3, there was a total of 13 871 person-
years (PY), with a median follow-up of 6.6 years for
HIV-seronegative and 5.9 years for HIV-seropositive
participants. With a total of 92 validated overdose deaths,
of which 69 were HIV seropositive (Table 3), the overall
overdose mortality rate was 6.6/1000 PY [95% con-
fidence interval (CI) 5.4, 8.1/1000 PY], with 5.6/1000
PY (95% CI 4.4, 7.1/1000 PY) for HIV-seronegative
drug users and 13.9/1000 PY (95% CI 9.4, 20.5/1000
PY) for HIV-seropositive drug users (P < 0.01). Figure 1
shows the complement of extended Kaplan–Meier on
the probability of overdose mortality by HIV infection
status through the follow-up, which was higher for
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HIV-seropositive than for uninfected participants (log
rank test P ¼ 0.03).
Table 3 also shows the hazard ratio (HR) of overdose
mortality by HIV infection serostatus from crude,
adjusted and weighted models, respectively. The unad-
justed HR of overdose death for HIV-seropositive versus
uninfected participants was 2.04. With the marginal
structural model adjusting for confounders associated
with both HIV seroconversion and overdose mortality,
the HR of overdose death by HIV status was 2.54. Using
the standard time-dependent Cox model, the HR was
2.06, representing approximately a 20% reduction
between weighted and adjusted models on the risk of
overdose mortality by HIV status.
Mechanism of the effect of HIV infection on
overdose mortality
Table 4 shows a comparison of the results from the
standard marginal structural model with the results of
extended marginal structural models that include
potential mediators as time-varying covariates. Each of
the following: injection frequency (12%), use of shooting
gallery (13%), needle sharing (13%), type of drugs
injected (12%), employment status (12%) was associated
with more than a 10% reduction on the association of
HIV infection and overdose death. Daily alcohol use was
associated with only a 5% reduction in the association of
HIV and overdose death. In model 1, adjusting for drug
use, daily alcohol use and employment reduced the
association of HIV infection and overdose death by
approximately 15%: the HR decreased from 2.54 in the
standard marginal structural model to 2.18 in the
extended marginal structural model 1. Among medical
conditions and healthcare factors, shortness of breath,
diarrhea, and a recent inpatient visit were each associated
with a 10% reduction on the association of HIV infection
and overdose death, whereas health insurance was
associated with a 5% reduction on the association
of HIV infection and overdose death. Adjusting for
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Table 1. Baseline information of injection drug users by HIV seroconversion status in Baltimore, Maryland 1988–2001.
Baseline characteristic
HIV seronegative (n U 1619) HIV seropositive (n U 308)
P valueN Proportion (%) N Proportion (%)
Demographic
Age (years)
< 30 347 21.4 117 38.0
30–40 824 50.9 152 49.4
40–50 389 24.0 34 11.0
> 50 59 3.6 5 1.6 < 0.01
Male education 1202 75.1 228 74.0 0.66
Less than high school 859 53.7 193 62.7
High school 342 21.4 55 17.9
Some college or more 398 24.9 60 19.5 0.04
Employed 295 18.5 64 20.8 0.35
Married or ever 613 38.4 95 30.8 0.01
Black race 1471 91.4 290 94.5 0.07
Drug use/treatment characteristic
Age of first drug use (years)
< 18 520 32.8 123 40.2
18–25 677 42.6 116 37.9
> 25 391 24.6 67 21.9 0.04
Injection pattern
No injection 253 16.4 48 15.9
£ 1/day 521 33.8 106 35.1
> 1/day 768 49.8 148 49.0 0.9
Type of drug use
Not injection 253 16.5 48 16.0
Cocaine 152 9.9 8 2.7
Heroin 141 9.2 41 13.6
Cocaine and heroin 989 64.4 204 67.8 < 0.01
Shared needles (yes) 845 53.3 148 48.5 0.12
Shooting gallery use (yes) 629 39.7 108 35.4 0.16
Methadone treatment (yes) 154 10.3 16 5.4 0.01
Detoxification programme (yes) 206 13.7 36 12.2 0.50
Other
Health insurance
No 575 37.4 105 35.1
Public insurance 787 51.2 170 56.9
Private insurance 174 11.3 24 8.0 0.11
Ever in jail (yes) 223 21.9 63 23.3 0.63
Sexual orientation
Heterosexual 1418 92.1 262 86.8
Male homosexual 80 5.2 33 10.9
Female homosexual 41 2.7 7 2.3 < 0.01
shortness of breath, diarrhea, a recent inpatient visit, and
health insurance reduced the association of HIV infection
and overdose by approximately 20%: from a HR of 2.54
in the standard marginal structural model to 2.06 (95% CI
1.17, 3.61). As shown in model 2, adjusting for both drug
use characteristics and medical conditions reduced the
association of HIV infection and overdose by almost 30%,
from an HR of 2.54 in the standard marginal structural
model to 1.82 (95% CI 1.01, 3.30, P ¼ 0.05) in the
extended marginal structural model 2.
The association of abnormal liver function with
overdose mortality
Overall, 1326 participants (69%) had liver function tests.
Adjusting for abnormal liver function in the marginal
structural model reduced the association of HIV and
overdose death by 12%. Adjusting for drug use
characteristics, medical conditions, healthcare, and
abnormal liver function together reduced the association
between HIVand overdose death by 35%, with a decrease
in the HR from 3.07 (95% CI 1.52, 6.18, P ¼ 0.002) in
the standard marginal structural model to 2.01 (95% CI,
0.96, 4.20, P ¼ 0.06) in the extended marginal structural
model. Also, abnormal liver function itself was associated
with a higher risk of overdose mortality (HR 2.00, 95%
CI 1.05, 3.84, P ¼ 0.04), by adjusting for drug and
alcohol use, drug abuse treatment, employment, medical
condition, and health insurance.
In addition, among participants who died from overdoses
and had autopsy reports (n ¼ 51), at the body examina-
tion, the median level of blood morphine, the proportion
with detected alcohol use, and the proportion of detected
multidrug use for HIV-seropositive and HIV-seronegative
drug users was 533 and 699 mg/l (P ¼ 0.62); 54.6 and
48.5% (P ¼ 0.73), and 81.8 and 96.8% (P ¼ 0.1),
respectively.
Discussion
The major finding of this study was the observation of a
higher rate of overdose mortality among those with HIV
infection. Factors accounting for approximately 35% of
the association between HIV infection and overdose
death included a combination of drug use behavior,
medical conditions, healthcare utilization and abnormal
liver function.
Our data are in contrast to a few previous studies that have
failed to identify a significant association of HIV infection
and overdose mortality. The COMCAT study from Italy
compared 474 HIV-prevalent IDU with 1958 IDU with
unknown HIV serostatus, followed from 1980 to 1991,
on the cause of mortality, and found no effect of HIV
infection on overdose death [6]. However, the general-
izability of the study was limited because: (i) hospital-
traced prevalent rather than incident cases were used; (ii)
the control group did not distinguish serostatus and
probably included HIV-seropositive IDU; and (iii) the
comparison was based on an unadjusted mortality rate.
Another study from New York City consisted of 318
The effect of HIV infection on overdose mortality Wang et al. 939
Table 2. Characteristics associated with HIV seroconversion for
1927 active drug users in Baltimore, Maryland 1988–2001.
Characteristic Adjusted RR 95% CI
Age (years)
30–40 versus < 30 0.61 0.44, 0.84
40–50 versus < 30 0.38 0.23, 0.63




less than high school
0.81 0.57, 1.17
College versus
less than high school
0.85 0.59, 1.21
Marriage 1.05 0.76, 1.45
Black 0.88 0.49, 1.59
Age of first drug use (years)
18–25 versus < 18 0.69 0.50, 0.94
> 25 versus < 18 0.83 0.57, 1.20
Time-varying covariates
Employment 0.72 0.51, 1.02
Marijuana use 0.71 0.52, 0.97
Drug injection less than
daily versus no
1.49 0.98, 2.25
Daily injection versus no 1.76 1.16, 2.66
Needle sharing 1.04 0.75, 1.45
Shooting gallery use 1.45 0.94, 2.25
Methadone treatment 0.38 0.18, 0.81
Detoxification programme 0.55 0.32, 0.94
Daily alcohol use 1.15 0.82, 1.62
Male homosexuality 2.14 1.34, 3.40
CI, Confidence interval; RR, risk ratio.
Table 3. Association of HIV on overdose mortality determined by marginal structural model and standard Cox model among 1927 active drug
users in Baltimore, Maryland 1988–2001.
Exposure No. of OD Person-years Mortality rate (/1000 PY) Crude HR (95% CI) Adjusteda (95% CI) Weighteda (95% CI)
HIV seronegative 67 12 067 5.6 (4.4, 7.1) 1 1 1
HIV seropositive 25 1804 13.9 (9.4, 20.5) 2.04 (1.28, 3.24) 2.06 (1.25, 3.38) 2.54 (1.47, 4.38)
Total 92 13 871 6.6 (5.4, 8.1)
CI, Confidence interval; HR, hazard ratio; OD, overdose death; PY, person-years.
aBoth the adjusted and the weighted models accounted for the same set of covariates: age, sex, race, marital status, education level, employment,
and age of drug initiation, injection frequency, needle sharing, and use of shooting gallery at baseline; as well as time-varying employment, drug
injection and frequency, detoxification programme, methadone treatment, needle sharing, shooting gallery, alcohol use and homosexual
orientation.
HIV-seropositive (14 were HIV seroconverters) and 411
HIV-seronegative IDU followed for a median of 3 years
[12]. Comparisons of crude overdose mortality rates did
not differ by HIV serostatus, but only three overdose
deaths were identified in the HIV-seropositive group.
Among studies that have identified a positive association
between HIV infection and overdose death, one study
had a similar result to ours [13], another observed a crude
relative risk of 3.6 [11], and three additional studies
[7,9,14] suggested a positive but lower magnitude of
effect of HIV infection on overdose mortality than that
reported here.
The mechanism of the impact of HIV infection on drug
overdose was explored through three hypotheses in this
study. First, drug use behavior may affect both HIV risk
and overdose, thus working as a confounder, but
alternatively HIV infection could affect drug use (i.e.
reduced use with HIV symptoms affecting tolerance to
drugs or cognitive function), which in turn could result in
a higher risk of overdose death. Studies have shown that
after HIV infection, drug users tend to reduce their drug
use [43] and risky sexual behavior [44], are less likely to go
to a shooting gallery [45] and share needles [43], but are
also more likely to seek medical care [46] and enroll into
drug treatment [47]. Studies have also shown that drug
users who died from (or experience non-fatal) overdoses
were individuals who had relapsed after ceased or reduced
drug use before the event [16,48]. Furthermore, drug
users who inject drugs in an environment in which they
have not used drugs before have decreased tolerance and a
higher risk of overdose mortality [18]. Drug users who are
enrolled in a drug treatment programme may also have a
higher risk of overdose as a result of reduced tolerance
that is associated with abstinence or infrequent drug use
during treatment [18,49]. In our study, adjusting for drug
injection frequency, the type of drug injected, the use of a
shooting gallery, and needle sharing reduced the
association of HIV and overdose death by approximately
15% in the extended marginal structural model. Also, the
results from autopsy reports showed lower morphine
levels and less multidrug use among HIV-seropositive
than seronegative drug users, suggesting that it is not
the dose that defines ‘overdose’, but rather these other
factors.
Second, HIV infection can undermine the immune
system and cause multisystem disorders. Certain syste-
matic diseases can be associated with a higher risk of
overdose mortality. Among them, pulmonary disease and
respiratory infection are two of the most plausible
diseases, because drug users with decreased pulmonary
function may be at increased vulnerability to fatal
respiratory depression, and therefore at a greater risk of
overdose death [2]. In our study, adjusting for shortness of
breath, diarrhea, a recent inpatient visit, and health
insurance status reduced the association of HIV and
overdose mortality by 20%. Both shortness of breath and





0 5 10 15













Fig. 1. Complement of Kaplan–Meier survival estimates by
HIV status.
Table 4. Association of HIV on overdose mortality adjusting for possible mediators in extended marginal structural models among 1927 injection
drug users in Baltimore, Maryland 1988–2001.a
Characteristics
Model 1 Model 2
HR 95% CI HR 95% CI
HIV 2.18 1.22, 3.89 1.82 1.01, 3.30
Injection heroin versus no injection 5.50 2.85, 10.61 5.11 2.48, 10.52
Injection cocaine versus no injection 2.03 0.58, 7.08 1.67 0.46, 6.13
Both heroin and cocaine versus no injection 4.77 2.50, 9.08 4.28 2.09, 8.75
Daily injection 0.69 0.43, 1.11 0.68 0.41, 1.13
Needle sharing 1.04 0.64, 1.69 0.96 0.59, 1.54
Shooting gallery 0.43 0.13, 1.41 0.42 0.13, 1.36
Employment 0.57 0.30, 1.09 0.60 0.30, 1.20
Diarrhea – – 2.03 0.82, 5.00
Shortness of breath – – 1.61 0.75, 3.42
Inpatient visit – – 2.09 1.24, 3.53
CI, Confidence interval; HR, hazard ratio.
aBothmodelswere extendedmarginal structuralmodels with the ‘mediators’ added as time-varying covariates. Daily alcohol, methadone treatment
and detoxification were included in both models, and health insurance was included in model 2 to control for confounding betweenmediators and
overdose deaths [42].
diarrhea tended to be associated with a higher risk of
overdose mortality. The association between diarrhea and
overdose death may be associated with the overall physical
health condition, or be an indicator of drug use
withdrawal symptoms.
Third, hepatic disease can impact the overdose mortality
through prolonging the metabolism of opiates. HIV
infection that is associated with the acceleration of HCV
progression may affect overdose mortality through
accelerated liver damage, therefore increasing vulner-
ability to fatal respiratory depression. Studies have shown
that co-infection of HIV among HCV patients has
resulted in a higher level of HCV viral load as a result of
damaged cellular immunity [50,51], resulting in sig-
nificantly accelerated liver fibrosis and cirrhosis, a poorer
response to interferon therapy and increased liver
necroinflammatory lesions, as well as resulting in an
increased risk of liver-related mortality [23–25,51]. This
effect has been shown to be more apparent among HIV-
infected individuals who have lower CD4 cell levels
[23,24], which is different from our sample that consisted
of HIV seroconverters. Given the median 8–10 years
latent period of HIV infection and the median 5.9 years of
follow-up for HIV seroconverters in our study, the impact
of HIV infection on overdose mortality through
accelerating liver function damage may be moderate.
Several study limitations should be acknowledged. The
small number of overdose deaths identified among the
HIV seroconverters identified during follow-up has
limited our ability to explore another hypothesis: the
higher risk of overdose death among HIV-seropositive
drug users may be associated with progressed immuno-
deficiency. A separate analysis that includes both HIV-
prevalent drug users and HIV-incident drug users may be
able to address this hypothesis. This can be further
considered by investigating whether highly active
antiretroviral therapy is associated with a lower risk of
overdose mortality by adjusting for treatment access
factors. Also, we did not have mental health information
about the participants during the follow-up; therefore, we
were unable to explore the hypothesis that HIV infection
may affect the mental health condition and therefore
increase the risk of overdose mortality, which has been
shown in recent studies [52,53]. In addition, our
population was limited to IDU; the association of HIV
and overdose deaths specifically in a population of non-
injectors merits further study.
In summary, our study demonstrates that HIV infection
and abnormal liver function is associated with a higher
risk of overdose mortality among active drug users. Drug
use behavior, systematic disease and liver function damage
associated with HIV infection accounted for approxi-
mately 35% of the effect of HIV on overdose deaths.
These findings suggest that special attention about
overdose prevention should be directed to individuals
with HIV infection who use illicit drugs. Potential
interventions include counseling at post-HIV testing
counseling, closer monitoring and easier access of drug
abuse treatment to drug users with HIV infection, and in
cities where naloxone is available, training those with
authority to prescribe or administer naloxone to drug
users, which has been shown substantially to reduce
overdose morbidity and mortality [54].
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